Emulsions containing arylboronic acids and medical articles made therefrom
View Patent ↗The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.
1. An emulsion comprising a hydrophobic polymer, an arylboronic acid, a continuous phase, and a discontinuous phase, wherein the hydrophobic polymer is in the discontinuous phase and the arylboronic acid is in the continuous phase.
2. The emulsion of claim 1 wherein the arylboronic acid comprises a halogenated arylboronic acid.
3. The emulsion of claim 2 wherein the halogenated arylboronic acid comprises a phenyl group, a boronic acid group, and at least one halogen atom, wherein the boronic acid group and the at least one halogen atom are attached to the phenyl group at positions on the phenyl ring.
4. The emulsion of claim 2 wherein the halogenated arylboronic acid is according to Formula I:
wherein one or more of R 1 , R 2 , R 3 , R 4 , and/or R 5 is selected from a halogen atom, and any R 1 , R 2 , R 3 , R 4 , and/or R 5 positions not occupied by a halogen atom are H.
5. The emulsion of claim 4 wherein the two of R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from halogen atoms.
6. The emulsion of claim 4 wherein the one or more of R 1 , R 2 , R 3 , R 4 , and/or R 5 are Cl.
7. The emulsion of claim 6 wherein R 2 and R 4 are Cl.
8. The emulsion of claim 2 comprising 3,5-dichlorophenylboronic acid.
9. The emulsion of claim 1 wherein the hydrophobic polymer comprises a degradable portion.
10. The emulsion of claim 1 wherein the hydrophobic polymer comprises a polysaccharide portion.
11. The emulsion of claim 10 wherein polysaccharide portion comprises poly-α(1→4)glucopyranose.
12. The emulsion of claim 1 wherein the hydrophobic polymer comprises a polymer backbone and a reactive group pendent from the polymer backbone.
13. The emulsion of claim 12 wherein the reactive group comprises a silyl ether group.
14. The emulsion of claim 1 wherein the hydrophobic polymer comprises a polymer backbone and a pendent group on the polymer backbone, the pendent group comprising a hydrocarbon group and a linker group between the hydrocarbon group and the polymer backbone, wherein the linker group comprises a silyl ether group.
15. The emulsion of claim 1 wherein the hydrophobic polymer is present at a concentration in the range of 0.005% wt to 5% wt.
16. The emulsion of claim 1 wherein the arylboronic acid is present at a concentration in the range of 0.005% wt to 5% wt.
17. The emulsion of claim 1 comprising a water-in-oil-in-water emulsion.
18. The emulsion of claim 1 further comprising a bioactive agent.
19. The emulsion of claim 1 comprising microparticulates comprising the hydrophobic polymer.
20. The emulsion of claim 19 wherein the microparticulates comprise a core comprising bioactive agent and a shell comprising the hydrophobic polymer.
21. A method for preparing an injectable or implantable medical material or article comprising steps of (a) preparing an emulsion comprising a hydrophobic polymer, an arylboronic acid, a continuous phase, and a discontinuous phase, wherein the hydrophobic polymer is in the discontinuous phase and the arylboronic acid is in the continuous phase, and wherein particulates comprising the hydrophobic polymer are formed in the emulsion, and (b) using the particulates for the preparation of, or as an injectable or implantable medical material or article.
22. The method of claim 21 wherein step (b) comprises forming the particulates into a medical implant.
23. Microparticles formed from a process comprising a step of preparing an emulsion comprising a hydrophobic polymer, an arylboronic acid, a continuous phase, and a discontinuous phase, wherein the hydrophobic polymer is in the discontinuous phase and the arylboronic acid is in the continuous phase, and wherein microparticles comprising the hydrophobic polymer are formed in the emulsion.
24. The emulsion of claim 1 wherein the continuous phase is an aqueous continuous phase.
25. The emulsion of claim 18 wherein the bioactive agent is selected from the group consisting of antibiotics, anti-coagulants, antihypertensive agents, anti-inflammatory agents, antiproliferatives, immunosuppressive agents, and steroids.